On August 13, 2026, Khartis Therapeutics, a biotechnology company developing both first- and best-in-class oral small molecule medicines for immunological and chronic diseases, announced that it has raised $50 million in Series B financing. The round was led by Forge Life Science Partners, with participation from Longwood Fund and Alexandria Venture Investments, alongside existing investors Foresite Capital, Lilly Asia Ventures, and Nextech Invest, bringing total capital raised to $95 million. Wilson Sonsini Goodrich & Rosati advised Khartis on patent matters related to the transaction and has served as patent counsel for the company since its inception in 2024.

The financing will support the advancement of Khartis’ lead program, the first oral, selective IGF-1R inhibitor designed specifically for the treatment of thyroid eye disease (TED), as well as the continued development of the company’s broader pipeline of oral small molecule medicines targeting clinically validated immunology pathways.

The Wilson Sonsini team that advised Khartis on patent matters includes Mike Hostetler, Celine Bonnefous, and Uale Taotafa.

For more information, please see Khartis’ news release. Additional information can be found on Fierce Biotech.